Accessibility Menu
Mosaic ImmunoEngineering logo

Mosaic ImmunoEngineering(OTC) CPMV

Current Price$0.67
Market Cap$4.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-86%
5 Year-62%
1 Year+68%
1 Month-0%
Mosaic ImmunoEngineering last closing stock price
MetricPriceDate
Last closeUSD 0.672026-07-22
Mosaic ImmunoEngineering stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.46%USD 0.642026-07-15
1 month-0.04%USD 0.672026-06-18
3 month-3.05%USD 0.692026-04-22
Year to date+116.62%USD 0.312025-12-31
1 year+67.59%USD 0.402025-07-22
3 year-32.63%USD 1.002023-07-21
5 year-61.5%USD 1.752021-07-23
Since inception-86.25%USD 4.902020-08-24

Mosaic ImmunoEngineering Financials at a Glance

Market Cap

$4.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$681.88K

EPS (TTM)

-$0.09

P/E Ratio

-7.15

Dividend

$0.00

Beta (Volatility)

-0.60 (Low)

Price

$0.67

Volume

400

Open

$0.33

Previous Close

$0.67

Daily Range

$0.33 - $0.67

52-Week Range

$0.31 - $1.05

Estimated Earnings Date

Apr 13, 2026

CPMV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering develops early-stage treatments for cancer and infectious diseases. Its main product uses plant-based nanoparticles to help the immune system fight illness. The company’s work aims to benefit both humans and animals needing new therapy options.

Lab Bench to Bedside: What Mosaic Sells

  • Immunomodulator platform: Technology designed to boost immune response against cancer and infections (0% of revenue).
  • MIE-101 candidate: Nanoparticle treatment from cowpea mosaic virus, non-infectious in humans and animals (0% of revenue).
  • Advisory services: Consulting for other biotech firms, such as Oncotelic (100% of reported income in 2025).

Growth Spurts and Growing Pains

  • Terminated exclusive license with Case Western Reserve University for core technology in March 2024.
  • Ended some technology agreements with UC San Diego in July 2023.
  • Entered a term sheet with Oncotelic Therapeutics in April 2024 to acquire cancer therapy rights; talks ongoing as of June 2025.
  • Provided advisory services to Oncotelic from July 2024 to February 2025.

Why Mosaic Is a Bit Different

Mosaic operates with a very small team and no physical offices. It focuses on early-stage research, relying on outside partners for manufacturing and development. The company’s only income comes from consulting, not product sales.

Five Things You Need to Know

  • No product sales or commercial revenue as of December 2025.
  • Operating loss was $616,119 in 2025, down approximately 30% from 2024.
  • Cash and equivalents were $3,622 at year-end 2025, with $6 million in liabilities.
  • Research and development spending fell 65% in 2025 versus 2024.
  • Company has only two full-time employees and no manufacturing facilities.

Bottom Line

Mosaic remains a pre-commercial biotech focused on early research and advisory work. Its future depends on securing new product candidates and funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Steven W. King

Website

www.mosaicie.com

Headquarters

Huntington Beach, CA 94947, US

CPMV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

9.22%

Return on Capital

N/A

Return on Assets

-6938.11%

Earnings Yield

-13.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.24M

Volume

400

Avg. Volume

222.984

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$596.15K

EBITDA

-$610.15K

Operating Cash Flow

-$166.84K

Capital Expenditure

$0.00

Free Cash Flow

-$166.84K

Cash & ST Invst.

$72.00

Total Debt

$1.48M

Mosaic ImmunoEngineering Performance Analysis

Mosaic ImmunoEngineering annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Mosaic ImmunoEngineering sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Mosaic ImmunoEngineering annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.33-40.1%
20232023-12-31USD -0.14-57.7%
20242024-12-31USD -0.13-8.5%
20252025-12-31USD -0.10-25.4%
Mosaic ImmunoEngineering sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.2%
Q32025-09-304.2%
Q42025-12-31-2.6%
Q12026-03-3114.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$697.00K

N/A

Employees

7

N/A

Net Income

-$175.35K

+3.3%

EBITDA

-$154.80K

+3.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$72.00

-99.9%

Total Debt

$1.48M

-7.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.48M

+5.2%

Short Term Debt

$0.00

-100.0%

Return on Assets

-69.38%

N/A

Return on Invested Capital

9.67%

N/A

Free Cash Flow

-$3.55K

+87.8%

Operating Cash Flow

-$3.55K

+87.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PHRRFPharmaTher Holdings Ltd.
$0.04+4.37%
CUBTCurative Biotechnology, Inc.
$1.00+5.00%
BIXTBioxytran, Inc.
$0.02+0.42%
TXTMProText Mobility, Inc.
$0.00-2.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.30-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.16+0.02%
CLFCleveland-Cliffs
$11.05+0.01%

Questions About CPMV

What is the current price of Mosaic ImmunoEngineering?

Mosaic ImmunoEngineering is trading at $0.67 per share.

What is the 52-week range for Mosaic ImmunoEngineering?

Over the past 52 weeks, Mosaic ImmunoEngineering has traded between $0.31 and $1.05.

How much debt does Mosaic ImmunoEngineering have?

As of the most recent reporting period, Mosaic ImmunoEngineering reported total debt of $1.68M.

How much cash does Mosaic ImmunoEngineering have on hand?

Mosaic ImmunoEngineering reported $72.00 in cash and cash equivalents in its most recent financial results.

What is Mosaic ImmunoEngineering’s dividend yield?

Mosaic ImmunoEngineering does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services